SCHEMBL844588

SCHEMBL844588

O=c1c2ccccc2[nH]c(=S)n1-c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 3/20 1.00
PDE7B Q9NP56 2/20 1.00
HTT P42858 1/20 0.79
ALDH1A1 P00352 6/20 0.73
RXFP1 Q9HBX9 2/20 0.73
L3MBTL1 Q9Y468 2/20 0.73
KDM4E B2RXH2 1/20 0.65
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA9 Q16790 1/20 0.64
LOXL3 P58215 1/20 0.61
LOXL2 Q9Y4K0 1/20 0.61
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.59
MAPT P10636 2/20 0.59
GAA P10253 1/20 0.59
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103233 1.00 PDE7A (1.00) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL31419817 0.87 PDE7A (0.77) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL6283505 0.87 PDE7A (0.77) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL18239987 0.87 PDE7A (0.77) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL14096394 0.87 PDE7A (0.77) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL3342878 0.85 ALDH1A1 (1.00) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL16896092 0.84 PDE7A (0.72) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL6306891 0.84 PDE7A (0.71) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL6283951 0.84 PDE7A (0.71) PDE7APDE7BHTTALDH1A1RXFP1
SCHEMBL6282946 0.84 ALDH1A1 (0.71) PDE7APDE7BHTTALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170231931-A1 PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-08-17 US claimed
EP-3185903-A1 PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES Fundación para la Investigación Médica Aplicada (ES) 2017-07-05 EP claimed
WO-2016030345-A1 PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2016-03-03 WO claimed
US-9192610-B2 Use of quinazoline derivatives for neurodegenerative diseases CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2015-11-24 US claimed
EP-2433637-B9 USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2015-06-10 EP claimed
EP-2433637-B1 USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2014-06-11 EP claimed
US-20120129877-A1 USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2012-05-24 US claimed
EP-2433637-A1 USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2012-03-28 EP claimed
US-20260060970-A1 Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance MITODICURE GMBH (DE) 2026-03-05 US disclosed
US-20230117674-A1 MICROFLUIDIC REACTOR FOR CONTROLLING CHEMICAL REACTION AND CHEMICAL REACTION CONTROL METHOD USING THE SAME POSTECH Research and Business Development Foundation (KR) 2023-04-20 US disclosed
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 US disclosed
US-9796687-B2 S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2017-10-24 US disclosed
US-9796687-B2 S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2017-10-24 US disclosed
US-20170231931-A1 PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-08-17 US disclosed
EP-2433637-A1 USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2012-03-28 EP disclosed
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
US-4824469-A PHENYL-, (1,2,4-TRIAZOL-1-YL- OR IMIDAZOL-1-YL-) QUINAZOLIN-4-(ONE OR THIONE) SCHERING AGROCHEMICALS LTD. (GB) 1989-04-25 US disclosed
US-4731106-A Fungicidal azole compounds SCHERING AGROCHEMICALS LIMITED (GB) 1988-03-15 US disclosed
EP-0183458-A1 Fungicidal azole compounds SCHERING AGROCHEMICALS LIMITED (GB) 1986-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170231931-A1 PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES SNCA, PSEN2, PSEN1 PDE7A 2054/4885PDE7B 519/4885HTT 7/4885
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 PDE7A 3371/4885PDE7B 3915/4885HTT 3057/4885
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv RNASE1, SARS1, EIF2AK2 PDE7A 3074/4885PDE7B 2971/4885HTT 3396/4885
US-20260060970-A1 Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance PDE5A, PDE4C, PDE12 PDE7A 5/4885PDE7B 14/4885HTT 2169/4885
US-20120129877-A1 USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES PARK7, SNCA, NLN PDE7A 867/4885PDE7B 409/4885HTT 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.